Most of our news have been distributed through our newsletter (subscribe here) and Facebook for the past year, but we’d like to update everyone who is not following us on those channels on the global availability and regulatory status of Sooma tDCS and Sooma Depression Treatment.
Major regulatory approvals
In the European union:
Sooma tDCS is a Class IIa medical device indicated for treatment of major depressive disorder.
Sooma tDCS is Health Canada Class II device indicated for treatment of chronic pain.
Sooma tDCS is a medical device under Therapeutic Goods Administration (TGA) and indicated for treatment of major depressive disorder.
We have been building local support networks for our customers worldwide, and currently our partners are able to provide local support for customers in following countries:
- Hong Kong
- New Zealand
- United Kingdom
Contact us at firstname.lastname@example.org if you wish further details on your local Sooma representative.
If your country is not on the list, do not worry. We will provide you with world-class support directly from Finland in English, Swedish, Finnish, French or Italian. Just email us at email@example.com in your preferred language or call +358 10 328 9811.